Navigation Links
Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics
Date:7/22/2008

Latest awards under Therapeutics Development Initiative bring MJFF's current active industry collaborations to 23; next deadline January 20, 2009

NEW YORK, July 22 /PRNewswire-USNewswire/ -- As part of its mission to speed delivery of transformative treatments and a cure for Parkinson's disease, The Michael J. Fox Foundation for Parkinson's Research has awarded $2.7 million in total funding to six industry research teams. The awards were granted under MJFF's Therapeutics Development Initiative (TDI) program. Open exclusively to researchers at biotech and pharmaceutical companies, TDI is the cornerstone of the Foundation's venture philanthropy efforts to spark and expand industry investment in PD drug development. In an increasingly risk-averse research funding climate, TDI helps to push promising candidate therapeutics forward in industry pipelines by allowing the Foundation to share the risk of drug development.

"At MJFF, our job is to do whatever it takes to speed therapeutics development for Parkinson's disease," said Katie Hood, CEO of The Michael J. Fox Foundation. "Early on we realized the critical importance of forging financial and intellectual partnerships with industry as well as academic research teams. Our private philanthropy dollars -- raised largely from patients themselves -- have a critical role to play in 'de-risking' therapeutic targets for industry investment in order to keep the most promising ideas moving forward toward clinical testing and pharmacy shelves."

Funded projects focus on:

-- Developing a vaccine that could protect against toxicity of the PD-implicated protein alpha-synuclein (Ingeborg Muehldorfer, Ph.D., Rentschler Biotechnologie, Laupheim, Germany);

-- Improving delivery of the gold-standard Parkinson's treatment, levodopa, which could lessen debilitating side effects of the drug including dyskinesias, the uncontrollable movements that arise with long-term levodopa therapy (Verne Cowles, Ph.D., and S. Y. Eddie Hou, Ph.D., Depomed, Inc., Menlo Park, California);

-- Validating a novel metabolomic diagnostic test for PD (Hyman Schipper, MD, PhD, FRCPC, and Peter Roos, Ph.D., Molecular Biometrics, Montreal, Canada);

-- Finding new ways to target the PD-implicated gene LRRK2 (Vicki Nienaber, Ph.D., Zenobia Therapeutics, San Diego, California);

-- Investigating methods to modulate the new PD target GPR88, a protein receptor believed to play a role in dopaminergic function (Thomas Sager, Ph.D., and Kenneth Thirstrup, Ph.D., H. Lundbeck A/S, Valby, Denmark); and

-- Exploring gene-knockout techniques to protect against oxidative stress implicated in the neuronal loss that characterizes PD (Kenneth Thirstrup, PhD, and Thomas Sager, Ph.D., H. Lundbeck A/S, Valby, Denmark).

Detailed grant abstracts and researchers' bios are available at http://www.michaeljfox.org.

While The Michael J. Fox Foundation has funded industry research teams since its inception, it launched the Therapeutics Development Initiative in 2006 as part of a proactive initiative to capture the attention and imagination of for-profit decision-makers and encourage them to allocate resources to Parkinson's drug development. In 2007, recognizing the increasing sophistication of many university drug development programs, the Foundation added a one-time-only "academic track" to fund non-industry-based teams working toward transformative PD treatments. The Foundation has committed about $24 million in total funding to industry to date. Slightly less than half of that total (over $10 million) has gone to the 20 projects funded through the Therapeutics Development Initiative thus far.

The deadline for pre-proposals under the next $2.5-million, industry-only funding round of TDI is January 20, 2009. The program will again seek to support preclinical development of Parkinson's disease therapies with potential to fundamentally alter disease course and/or improve treatment of symptoms above and beyond current standards of care. Proposals must focus on key and critical preclinical studies necessary for developing, optimizing and evaluating therapeutic strategies that if successful can move into human testing. Full information for prospective applicants is available at http://www.michaeljfox.org.

About The Michael J. Fox Foundation

Founded in 2000, The Michael J. Fox Foundation for Parkinson's Research is dedicated to ensuring the development of a cure for Parkinson's disease within the coming decade through an aggressively funded research agenda. The Foundation has funded approximately $126 million in research to date.


'/>"/>
SOURCE Michael J. Fox Foundation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Michael J. Fox Foundation Awards $2.4 Million for Validation of Nine Promising Therapeutic Targets for Parkinsons Disease
2. The Foundation for Biomedical Research Announces Winners of the 7th Annual Michael E. DeBakey Journalism Awards
3. Michael J. Fox Foundation Announces $5.6-Million Award for Phase 2 Clinical Trial Studying Neuroprotective Potential of Inosine
4. Michael J. Fox Foundation Commits up to $10 Million for Pre-Clinical Drug Development Under Therapeutics Development Initiative
5. New Michael J. Fox Foundation Initiative Will Drive Development of Web-Based Tools to Increase Patient Participation in Parkinsons Clinical Trials
6. Michael J. Fox Foundation Commits Up to $3 Million for Clinical Trials That Can Improve Treatment of Parkinsons Disease
7. Michael J. Fox Foundation Awards Up to $3 Million to Industry Teams to Jumpstart Promising PD Drug Development
8. PTC Therapeutics Announces $25 Million Award From Cystic Fibrosis Foundation Therapeutics for Development of PTC124
9. Childrens Brain Tumor Foundations Tissue Bank Consortium May Solve Dire Problem in Pediatric Cancer Research
10. Canopus BioPharma Strengthens its CB1400 Platform Technology for Mucositis and Oncology Treatments Through License Agreement With Wisconsin Alumni Research Foundation
11. Quantum Immunologics, Inc. and the South Alabama Medical Science Foundation Announce an Early Clinical Evaluation of a Novel Immuno-therapeutic Vaccine for Treating Advanced Human Breast Carcinomas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... April 29, 2016 Glycotope GmbH, ... today announces the appointment of Dr. Alfredo Zurlo ... is an oncologist with many years clinical experience and ... industries. His last role was at Mologen AG where ... Executive Board. Previously Dr. Zurlo held various positions at ...
(Date:4/28/2016)...  While Abbott,s announced purchase of St. Jude ... and stent business, healthcare research firm Kalorama Information ... into patient monitoring.  Kalorama said that patient monitoring ... with double-digit growth expected the next 5 years, ... Patient Monitoring . Abbott Laboratories agreed to ...
(Date:4/28/2016)... 2016 Dr. ... und Stephen Schmidt werden ... ArisGlobal®, ein führender Anbieter cloudbasierter Softwarelösungen für ... dass neue Führungskräfte zum Team Sicherheit und ... vielfältige Erfahrungen mitbringen.  Dies wird die Geschäftseinheit ...
Breaking Medicine Technology:
(Date:4/30/2016)... ... April 30, 2016 , ... Orlando-based Maximized Living has ... go for gold in Rio. Under the care of Maximized Living doctors at ... In an unprecedented showing, Maximized Living is sending the largest contingent of elite chiropractors ...
(Date:4/29/2016)... ... April 29, 2016 , ... Memorial ... for Graduate Medical Education (ACGME) that it has received accreditation for its residency ... of three residency programs that Memorial is currently pursuing, including Pediatrics and Internal ...
(Date:4/29/2016)... ... April 29, 2016 , ... Dr. Bernie Siegel, ... "LOVE, MEDICINE and MIRACLES") addresses touchy topics related to Death live on ... Dr. Bernie Siegel, author of a plethora of essential books-to-read for physicians ...
(Date:4/29/2016)... ... ... Spine Team Texas, a comprehensive spine physician group specializing in the treatment of ... invited to be a featured speaker at the Texas Society of the American College ... , Dr. R. Scott McPherson, a physical medicine and rehabilitation specialist, will speak ...
(Date:4/29/2016)... ... ... the deadliest type of skin cancer. Although only about 1 percent of skin cancer cases ... 10,000 people are expected to die of melanoma this year. The risk increases with age, ... most commonly diagnosed cancers in young women. A recent breakthrough in genetic studies may give ...
Breaking Medicine News(10 mins):